PMID- 19967487
OWN - NLM
STAT- MEDLINE
DCOM- 20100331
LR  - 20211020
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 14
IP  - 6
DP  - 2009 Dec
TI  - Safety of bevacizumab treatment in combination with standard chemotherapy for 
      metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
PG  - 513-7
LID - 10.1007/s10147-009-0911-6 [doi]
AB  - BACKGROUND: Bevacizumab (BV) prolongs overall survival and progression-free 
      survival when combined with standard chemotherapy for metastatic colorectal 
      cancer (mCRC). However, because this drug was approved in Japan only in 2007, 
      there has been little experience in Japan. This study was conducted to evaluate 
      retrospectively the safety of BV in clinical practice. METHODS: Sixty-five 
      consecutive mCRC patients who received BV at our institution between June 2007 
      and March 2008 were selected. All patients were treated with chemotherapy in 
      combination with BV. We surveyed the medical records of all patients for adverse 
      events (AEs). We assessed the AEs using the Common Terminology Criteria for 
      Adverse Events version 3.0. RESULTS: The characteristics of the subjects were: 
      male, 45 patients; median age, 57 years; Eastern Cooperative Oncology Group 
      (ECOG) performance status (PS) 0-1, 62 patients; number of prior chemotherapy 
      regimens 0/1/ > 2, 15/28/22 patients. The incidence of BV therapy-related AEs of 
      all grades was: hypertension, 47.7%; proteinuria, 33.8%; bleeding, 35.3%; 
      gastrointestinal (GI) perforation, 3.1%; thrombosis, 7.7%; and wound-healing 
      complications, 6.2%. The incidence of grade 3/4 AEs related to BV therapy was: 
      hypertension, 13.8%; bleeding, 1.5%; GI perforation, 1.5%; and thrombosis, 4.6%. 
      Four patients (6.2%) had to stop chemotherapy because of the development of BV 
      therapy-related AEs. New events of hypertension, bleeding, and proteinuria 
      emerged until 120 days and thereafter. CONCLUSION: The incidence of BV 
      therapy-related AEs in this study was consistent with that observed in Western 
      prospective clinical trials, with the exception of hypertension and proteinuria. 
      A careful follow up is recommended for up to 120 days after the initiation of BV 
      administration.
FAU - Tamiya, Akihiro
AU  - Tamiya A
AD  - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
FAU - Yamazaki, Kentaro
AU  - Yamazaki K
FAU - Boku, Narikazu
AU  - Boku N
FAU - Machida, Nozomu
AU  - Machida N
FAU - Kojima, Takashi
AU  - Kojima T
FAU - Taku, Keisei
AU  - Taku K
FAU - Yasui, Hirofumi
AU  - Yasui H
FAU - Fukutomi, Akira
AU  - Fukutomi A
FAU - Hironaka, Shuichi
AU  - Hironaka S
FAU - Onozawa, Yusuke
AU  - Onozawa Y
LA  - eng
PT  - Journal Article
DEP - 20091205
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal/administration & dosage/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bevacizumab
MH  - Colorectal Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2009/12/08 06:00
MHDA- 2010/04/01 06:00
CRDT- 2009/12/08 06:00
PHST- 2008/12/26 00:00 [received]
PHST- 2009/05/24 00:00 [accepted]
PHST- 2009/12/08 06:00 [entrez]
PHST- 2009/12/08 06:00 [pubmed]
PHST- 2010/04/01 06:00 [medline]
AID - 10.1007/s10147-009-0911-6 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2009 Dec;14(6):513-7. doi: 10.1007/s10147-009-0911-6. Epub 2009 
      Dec 5.